Abbott secures European clearance for dual glucose/ketone device
By HME News Staff
Updated 9:42 AM CDT, Wed May 27, 2026
ABBOTT PARK, Ill. – Abbott has secured CE Mark for a dual glucose ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, providing real-time visibility into both glucose levels needed for daily diabetes management and rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency. The company says this marks the first time people with diabetes will be able to monitor ketones without traditional blood or urine tests. "Abbott has a long-established pattern of setting the pace in health tech innovation," said Chris Scoggins, executive vice president of Abbott's diabetes care business. "People living with diabetes routinely tell us that the risk of serious complications is a constant part of everyday life. Our Libre Duo systems offer people with diabetes, families and healthcare providers clearer, earlier information about what's happening inside their body, allowing them to act sooner when safety matters most." Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo systems will integrate with Abbott's Libre digital health ecosystem, enabling users to share glucose and ketone data with caregivers and healthcare providers. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. Libre Duo systems are not yet cleared or available for sale in the United States.
Comments